What is it about?

Our findings demonstrate that in atrial fbrillation patients treated with vitamin K antagonists, impaired fibrinolysis predisposes to thromboembolism, but not to bleeding.

Featured Image

Why is it important?

Our study suggests that clot lysis time (CLT) may provide additional prognostic information for anticoagulated patients with AF

Perspectives

The present study supports the concept of a biomarker-based approach in thromboembolic risk assessment in patients with AF. We demonstrated that clot lysis time (CLT) may refine clinical risk stratification of cerebrovascular events because the highest risk ofstroke or TIA during follow-up was observed in AF patients with high-risk clinical criteria combined with prolonged CLT. It might be speculated that CLT could be incorporated in the risk scales of AF-related thromboembolic events, and its assessment may help to adjust initial risk as reported in pa- tients following acute coronary syndrome

Leszek Drabik
Uniwersytet Jagiellonski w Krakowie

Read the Original

This page is a summary of: Clot Lysis Time Predicts Stroke During Anticoagulant Therapy in Patients with Atrial Fibrillation, Canadian Journal of Cardiology, August 2019, Elsevier, DOI: 10.1016/j.cjca.2019.08.001.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page